Volume Alert - SLXP 98.62 Salix Pharmaceuticals $SLXP Hit a

New Post Public Reply Private Reply Replies (0) Message Board

Nov 14, 2014 at 2:04 PM

Volume Alert - SLXP 98.62 Salix Pharmaceuticals $SLXP Hit a high today of 100.29 Closing the day 10:30 at 98.62 +1.63 +1.68% With a day low of 97.98 and a total volume of 1,061,125.

SLXP Recent Posts: http://investorshangout.com/Salix-Pharmaceuti...LXP-55453/

SLXP Salix Pharmaceuticals Recent Headline News

Upgrade Alert for Salix Pharmaceuticals (SLXP)
Comtex SmarTrend(R) - Fri Nov 14, 7:05AM CST
Salix Pharmaceuticals (NASDAQ:SLXP) was upgraded from Neutral to Buy at UBS today. The stock closed yesterday at $96.99 on volume of 3.9 million shares, above average daily volume of 2.9 million. There is potential upside of 73.8% for shares of Salix Pharmaceuticals based on a current price of $96.99 and an average consensus analyst price target of $168.59. Salix Pharmaceuticals shares should first meet resistance at the 200-day moving average (MA) of $124.39 and find additional resistance at the 50-day MA of $142.49.
SLXP: 100.20 (+3.21)

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Salix Pharmaceuticals, Ltd. to Contact Brower Piven Before the January 6, 2015 Lead Plaintiff Deadline in Class Action Lawsuit -- SLXP
GlobeNewswire - Thu Nov 13, 7:52PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company"

(Nasdaq:SLXP) securities during the period between November 7, 2013 and November 6, 2014, inclusive (the "Class Period"

. Investors who wish to become proactively involved in the litigation have until January 6, 2015 to seek appointment as lead plaintiff.
SLXP: 100.20 (+3.21)

Lieff Cabraser Announces Class Action Litigation Against Salix Pharmaceuticals, Inc. - SLXP
Business Wire - Thu Nov 13, 2:05PM CST
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been brought on behalf of those who purchased or otherwise acquired the securities of Salix Pharmaceuticals, Inc. ("Salix" or the "Company"

(NasdaqGS: SLXP) between November 8, 2013 and November 6, 2014, inclusive (the "Class Period"

.
SLXP: 100.20 (+3.21)

Robbins Arroyo LLP: Salix Pharmaceuticals, Ltd. (SLXP) Misled Shareholders According to a Recently Filed Class Action
GlobeNewswire - Wed Nov 12, 6:05PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) has filed a federal securities fraud class action complaint in the U.S. District Court for the Southern District of New York. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between November 8, 2013 and November 6, 2014. Salix is a pharmaceutical company that focuses on treatments for digestive system diseases and disorders.
SLXP: 100.20 (+3.21)

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Salix Pharmaceuticals Ltd and Certain Officers -- SLXP
GlobeNewswire - Wed Nov 12, 5:21PM CST
Pomerantz LLP has filed a class action lawsuit against Salix Pharmaceuticals Ltd ("Salix" or the "Company"

(Nasdaq:SLXP) and certain of its officers. The class action, filed in United States District Court, Eastern District of North Carolina, Western Division, and docketed under 14-cv-00804, is on behalf of a class consisting of all persons or entities who purchased Salix securities between August 7, 2014 and November 6, 2014, inclusive (the "Class Period"

. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act"

.
SLXP: 100.20 (+3.21)

SHAREHOLDER ALERT: Investors of Salix Pharmaceuticals, Ltd. with Losses of $250,000 or More Are Encouraged to Contact Glancy Binkow & Goldberg LLP
Business Wire - Wed Nov 12, 11:32AM CST
Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of a class (the "Class"

comprising purchasers of the securities of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company"

(NASDAQ:SLXP) between November 7, 2013 and November 6, 2014, inclusive (the "Class Period"

. Investors who have losses of $250,000 or more are encouraged to contact the firm for more information.
SLXP: 100.20 (+3.21)

INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Salix Pharmaceuticals Inc. (SLXP) To Contact The Firm
PR Newswire - Tue Nov 11, 4:23PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Salix Pharmaceuticals Inc. ("Salix" or the "Company"

(NASDAQ: SLXP) of the January 6, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Salix and certain executives.
SLXP: 100.20 (+3.21)

Lifshitz & Miller Law Firm Announces Investigation of Barrett Business Services, Inc., Bio-Rad Laboratories, Inc., Pingtan Marine Enterprise Ltd., Rayonier Inc. and Salix Pharmaceuticals, Ltd.
PR Newswire - Tue Nov 11, 11:10AM CST
Barrett Business Services, Inc.
RYN: 26.01 (-0.12), BIO: 111.42 (-0.12), BBSI: 22.76 (+0.46), SLXP: 100.20 (+3.21), PME: 1.33 (unch)

Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.81 (+0.06), AGN: 198.23 (+2.02), ACT: 244.31 (+2.68), VRX: 134.53 (+2.63), MDT: 69.11 (-0.27), SLXP: 100.20 (+3.21), SNY: 46.59 (+0.06)

Pharma Equities Technical Data - Salix Pharma, AstraZeneca, Novartis, Impax Laboratories, and Novo Nordisk
PR Newswire - Tue Nov 11, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Impax Laboratories Inc. (NASDAQ: IPXL), and Novo Nordisk A/S (NYSE: NVO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 10, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,613.74, up 0.23% and the NASDAQ Composite closed at 4,651.62, up 0.41%. The S&P 500 finished the session 0.31% higher at 2,038.26. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.00, up 1.00%, with the index gaining 11.86% in the previous three months. Register for your complimentary reports on these five stocks at:
IPXL: 28.83 (-0.23), NVO: 43.97 (-0.05), AZN: 72.78 (-1.75), SLXP: 100.20 (+3.21), NVS: 93.77 (-0.61)

Hagens Berman Alerts Investors of Lead Plaintiff Deadline in Class Action Lawsuit Filed Against Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP)
GlobeNewswire - Tue Nov 11, 7:38AM CST
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, alerts investors that a class action lawsuit has been filed against Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) ("Salix" or "the Company). The suit is pending in U.S. District Court for the Southern District of New York, and investors have until January 6, 2015 to move for lead plaintiff.
SLXP: 100.20 (+3.21)

Salix Pharmaceuticals: What Scares Me Most About Its High Inventory & Stock Collapse
Brian Nichols - at Seeking Alpha - Tue Nov 11, 6:50AM CST

SLXP: 100.20 (+3.21)

SALIX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Salix Pharmaceuticals Ltd. - SLXP
GlobeNewswire - Mon Nov 10, 9:00PM CST
Kahn Swick & Foti, LLC ("KSF"

and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 6, 2015 to file lead plaintiff applications in a securities class action lawsuit against Salix Pharmaceuticals Ltd. (Nasdaq:SLXP) if they purchased the Company's securities between November 8, 2013 and November 6, 2014, inclusive (the "Class Period"

. This action is pending in the United States District Court for the Southern District of New York.
SLXP: 100.20 (+3.21)

Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Salix Pharmaceuticals, Ltd.
Business Wire - Mon Nov 10, 3:28PM CST
Rigrodsky & Long, P.A.:
SLXP: 100.20 (+3.21)

SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Salix Pharmaceuticals, Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of January 6, 2015 -- SLXP
GlobeNewswire - Mon Nov 10, 3:11PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Salix Pharmaceuticals, Ltd. ("Salix" or the "Company"

(Nasdaq:SLXP) securities between November 8, 2013 and November 6, 2014.
SLXP: 100.20 (+3.21)

Salix Crashes on Inventory Issues, Lowered Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Nov 10, 1:56PM CST
Salix's (SLXP) wholesale inventory levels for its products were much higher than previously announced.
AGN: 198.23 (+2.02), VRX: 134.53 (+2.63), AUXL: 32.25 (-0.10), SLXP: 100.20 (+3.21)

Wolf Popper LLP Announces Investigation on Behalf of Investors in Salix Pharmaceuticals Ltd.
PR Newswire - Mon Nov 10, 11:09AM CST
Wolf Popper LLP is investigating potential claims on behalf of investors in Salix Pharmaceuticals Ltd. ("Salix"

common stock (NASDAQ: SLXP) during the period May 10, 2013 through November 6, 2014, concerning possible violations of federal securities laws. Such investors are advised to contact Fei-Lu Qian at 877.370.7703 or fqian@wolfpopper.com.
SLXP: 100.20 (+3.21)

Morgan & Morgan Announces That a Class Action Lawsuit Has Been Filed Against Salix Pharmaceuticals Ltd. -- SLXP
GlobeNewswire - Mon Nov 10, 10:40AM CST
Morgan & Morgan announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Salix Pharmaceuticals Ltd. ("Salix" or the "Company"

(Nasdaq:SLXP) securities between November 8, 2013 and November 6, 2014, inclusive (the "Class Period"

.
SLXP: 100.20 (+3.21)

Biotech Weekly: When Mid Caps Are Priced Nearly For Perfection
Daniel Ward - at Seeking Alpha - Mon Nov 10, 9:28AM CST

XBI: 167.53 (-3.81), SLXP: 100.20 (+3.21), ICPT: 161.00 (+2.14), IBB: 287.53 (-6.36), AGIO: 83.57 (-2.92)

Trade-Ideas: Salix Pharmaceuticals (SLXP) Is Today's "Dead Cat Bounce" Stock
at The Street - Mon Nov 10, 8:51AM CST
Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as a "dead cat bounce" (down big yesterday but up big today) candidate
SLXP: 100.20 (+3.21)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Fibocom LTE Modules Test Drive Satellite Connectivity

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Quantum Space Joins $185M NASA Lunar Transport Deal

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

ASTS Faces Class Action; Investors Beware of Pitfalls

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

D-Wave's Legal Trouble: Securities Fraud Suit Looms

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...